Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer

BACKGROUND AND OBJECTIVES: Brigatinib is an oral tyrosine kinase inhibitor approved in multiple countries for the treatment of patients with anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer who have progressed on or are intolerant to crizotinib. We report a population pharma...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Neeraj, Wang, Xiaohui, Offman, Elliot, Prohn, Marita, Narasimhan, Narayana, Kerstein, David, Hanley, Michael J., Venkatakrishnan, Karthik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862202/
https://www.ncbi.nlm.nih.gov/pubmed/32816246
http://dx.doi.org/10.1007/s40262-020-00929-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862202/
https://www.ncbi.nlm.nih.gov/pubmed/32816246
http://dx.doi.org/10.1007/s40262-020-00929-4

Ejemplares similares